Back to search
FDAFDA · Food and drugs·Recall number D-0261-2023

Conzerol zero molluscum contagiosum, Homeopathic treatment for Molluscum Contagiosum, Topical Cream, Net weight 0.78 oz (22g) tube, UPC 8 60322 00180 8, Manufactured by: Dr. Retter EC Warszawska 17, 05-075 Warszawa Poland

Published February 8, 2023 · Recall initiated: November 9, 2022

Summary

FDA records drug Class II recall D-0261-2023, published February 8, 2023 and initiated November 9, 2022. Recalling firm: DISCOVERY PHARMA LLC; Status: Terminated; Reported quantity: 21,892 tubes; Lot: Lots: 22123 Exp. 01/2024; 21732 Exp. 07/2023. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

CGMP deviations

What to do

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
DISCOVERY PHARMA LLC
Distributor
CA, FL, WA
Lot
Lots: 22123 Exp. 01/2024; 21732 Exp. 07/2023
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Conzerol zero molluscum contagiosum, Homeopathic treatment for Molluscum Contagiosum, Topical Cream, Net weight 0.78 oz (22g) tube, UPC 8 60322 00180 8, Manufactured by: Dr. Retter EC Warszawska 17, 05-075 Warszawa Poland recalled?

Yes. FDA published recall D-0261-2023 on February 8, 2023. Reported hazard: CGMP deviations

What should I do if I have this product?

Voluntary: Firm initiated · Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit